Skip to main content
Faye Feller, MD, Oncology, New York, NY

FayeMiriamFellerMD

Oncology • New York, NY

Hematologic Oncology

Physician

Join to view full profile

Dr. Feller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Feller's full profile

Already have an account?

  • Office

    1275 York Ave
    New York, NY 10065
    Phone+1 212-639-2000

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2007 - 2010
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 2007

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2009 - 2024

Publications & Presentations

PubMed

Abstracts/Posters

  • Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapse...
    Faye Feller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (Imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
    Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (Imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior TherapiesDecember 10th, 2024
  • Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (Imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
    Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (Imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with MyelofibrosisDecember 10th, 2024
  • Geron Announces New Data to Be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (Imetelstat) in Myeloid Hematologic Malignancies
    Geron Announces New Data to Be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (Imetelstat) in Myeloid Hematologic MalignanciesNovember 5th, 2024
  • Join now to see all

Dr. Faye Feller, Dr. Faye Feller, MD, Dr. F Feller, Dr. Faye Miriam Feller